1. Executive Summary (Confidence: High)

Liom (formerly known as Spiden) is a leading innovator in the $160 billion+ wearable health market, recently achieving a monumental technical breakthrough in Raman spectroscopy miniaturization. Headquartered in Pfäffikon, Switzerland, the company has secured a total of $80 million in funding to date, including a $16. million Series A extension in late 2025. Liom’s "world-first" achievement is the development of a calibration-free, non-invasive glucose-monitoring wearable that fits within a standard smartwatch form factor while maintaining a >24-hour battery life. Clinical results published in 2025 demonstrate a Mean Absolute Relative Difference (MARD) of 14.5%, placing its accuracy on par with first-generation invasive CGMs. Led by serial entrepreneur Leo Grünstein and supported by a board including Marc Maurer (former co-CEO of On Running), Liom is poised to disrupt the metabolic health sector when it launches its consumer device in 2028. The following table summarizes Liom’s technical and commercial milestones.